Adverum Biotechnologies (NASDAQ:ADVM): Q2 GAAP EPS of -$0.23 beats by $0.04.
Cash and equivalents of $97.81M.
Shares -0.32%.
Thursday, August 8, 2019
Spectrum Pharmaceuticals EPS beats by $0.13
Spectrum Pharmaceuticals (NASDAQ:SPPI): Q2 Non-GAAP EPS of -$0.23 beats by $0.13; GAAP EPS of -$0.26 beats by $0.10.
Cash and equivalents of $282M.
Aimmune Therapeutics EPS misses by $0.08
Aimmune Therapeutics (NASDAQ:AIMT): Q2 GAAP EPS of -$1.01 misses by $0.08.
Cash and equivalents of $72.56M
Dicerna Pharmaceuticals EPS misses by $0.04, misses on revenue
Dicerna Pharmaceuticals (NASDAQ:DRNA): Q2 GAAP EPS of -$0.35 misses by $0.04.
Revenue of $5.68M (+268.8% Y/Y) misses by $6.07M.
FDA rejects Kala Pharma’s KPI-121 for dry eye
Kala Pharmaceuticals (NASDAQ:KALA) may encounter some volatility after receiving a CRL from the FDA regarding its marketing application for dry eye disease candidate KPI-121. The agency stated that another clinical will be needed.
The company says results from its ongoing Phase 3 study, STRIDE 3, should be sufficient to address the FDA’s request. It expects to refile the application in H1 2020.
Shares are currently up 14% after hours.
Puma Biotechnology EPS beats by $0.42, beats on revenue
Puma Biotechnology (NASDAQ:PBYI): Q2 Non-GAAP EPS of -$0.57 beats by $0.42; GAAP EPS of -$0.97 beats by $0.02.
Revenue of $53.9M (+6.1% Y/Y) beats by $0.5M.
Shares +0.1%.
Accelerate Diagnostics EPS beats by $0.01, misses on revenue
Accelerate Diagnostics (NASDAQ:AXDX): Q2 GAAP EPS of -$0.38 beats by $0.01.
Revenue of $1.81M (+7.1% Y/Y) misses by $0.77M.
Subscribe to:
Posts (Atom)